# NCT02538198 (NCT02538198)

> Lenalidomide Maintenance in Plasma Cell Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02538198
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Plasma Cell Myeloma
- Interventions: Lenalidomide
- Enrollment: 108
- Primary outcome: progression-free survival

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02538198